Why the study?
Low-grade chronic systemic inflammation driven by inflammatory factors produced by hypertrophic adipose tissue in obesity is considered a driver of type 2 diabetes, liver and cardiovascular disease, and neurological disorders.
This review highlights the role of adipose tissue-derived inflammatory cytokines in driving obesity-related metabolic and cardiovascular disorders, and discusses potential therapeutic interventions.
Answers are grounded in this paper and cite their sources.
Adipose inflammation links obesity to cardiometabolic risk; extends cytokine mechanisms while leaving targeted therapies open.
Obesity increases the risk for a number of diseases, including type 2 diabetes, liver and cardiovascular disease, or neurological disorders. Low-grade chronic systemic inflammation typically accompanying obesity is considered driving these disorders. The inflammatory factors produced by the hypertrophic adipose tissue can have systemic effects. The present review summarizes current knowledge on the most investigated in this context, inflammatory cytokines: Tumor necrosis factor (TNF), interleukin 6 (IL6), IL1β, and interferon γ. Their metabolic effects on organs such as the liver, the skeletal muscle, the pancreas and the brain, and therapeutic interventions targeting systemic inflammation in obesity are discussed.
No takes yet. Share an insight, caveat, or question.
Vasileia Ismini Alexaki (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: